On November 2nd, it was learned from Pfizer that during the 7th China International Import Expo, Pfizer will showcase 24 globally leading innovative products and solutions under the theme of "Pfizer 35 China Beyond Yesterday to the Future", with 4 of them making their debut. In addition to showcasing its innovative capabilities, Pfizer China's 2030 strategy will also be released during this year's CIIE, demonstrating its commitment to continuously cultivating China in the future.
Jean Christophe Pointeau, President of Pfizer China, Chairman of RDPAC Executive Committee, and Vice President of China Association of Foreign Investment Enterprises, told Shanghai Securities News reporters that Pfizer has participated in the CIIE for six consecutive times. The CIIE is not only a platform for Pfizer to showcase its latest medical achievements, but also a window to convey Pfizer's long-term commitment to the Chinese market and care for Chinese patients. This year marks Pfizer's 35th year of development in China. At this important moment, the launch and implementation of Pfizer China's 2030 strategy will help accelerate the extension of the biopharmaceutical industry to the high-end of the value chain and improve the health and well-being of Chinese patients. This is our commitment to the Chinese market and our commitment to Chinese patients
Bring 60 innovative drugs and new indications to Chinese patients within a decade
It is reported that Pfizer China's 2030 strategy will be officially released to the public at the opening ceremony of the CIIE on November 6th. In the next five years, Pfizer will continue to invest in accelerating innovation, improving diagnostic capabilities and treatment standards, and promoting the development of the local biotechnology industry to help achieve the "Healthy China 2030" strategic goals as soon as possible.
We have set an exciting goal of 'triple speed innovation in China', striving to bring 60 innovative drugs and new indications to Chinese patients through accelerated innovation research and development in the decade from 2021 to 2030. Jean Christophe Pointeau revealed that Pfizer will work closely with the Chinese government and various sectors of society to accelerate research and development, promote innovation, improve the accessibility of emergency drugs and vaccines, and stand at the forefront of cancer treatment, helping China establish a strong and sustainable health innovation ecosystem, transform scientific research into effective drugs, and provide assistance to cancer and other non communicable disease patients.
It is reported that according to Pfizer China's 2030 strategy, Pfizer's newly built R&D center in Beijing will upgrade Pfizer's existing global innovative drug research and development layout in China, and play a leading role in Pfizer's innovative drug development in China, promoting the efficient implementation of the China Al In strategy, and including China in the early clinical stages of Pfizer's innovative drugs and vaccines, as well as the global synchronous development of all key Phase 3 studies.
In addition, as an important component of Pfizer China's 2030 strategy, Pfizer will also rely on its own resources, scale, and professional knowledge to promote biotechnology innovation throughout the entire life cycle from clinical research and development to drug development.
Jean Christophe Pointeau said, "Through the Pfizer Ignite program, Pfizer will provide more necessary support and services to local biotechnology partners in China, helping China accelerate innovation to meet global standards. We hope to better promote the development of the local biopharmaceutical industry and help more local companies bring their innovative drugs to the world
It is reported that Pfizer's Ignite program was first launched at last year's CIIE, and over the past year, it has established deep cooperation with Chinese partners. Currently, Huirui is assisting Beijing Tianguangshi Biotechnology Co., Ltd. in providing innovative treatment solutions for multiple myeloma patients through this program.
Showcasing scientific breakthroughs: 24 innovative products showcased at Pfizer booth
Innovative drugs have been a key keyword in the development of China's biopharmaceutical industry in recent years, and also a focus of efforts from various parties.
During the CIIE, Pfizer will bring 24 globally leading innovative products and solutions in the fields of oncology, anti infection, inflammation and immunity, rare diseases, migraine, vaccines, etc. Among them, 4 will debut in China for the first time, namely: the world's first combination of β - lactam/β - lactam inhibitor for metal β - lactam enzymes (MBLs), Sifonor (injectable amtreonam avibactam sodium), a new dual mechanism PARP inhibitor for prostate cancer, tazolazopanib tosylate capsules, a hemophilia therapy with unique mechanism of action, Mataxidan antibody, and a bispecific antibody targeting B cell mature antigen and CD3, Enatuzumab, etc.
In addition, Pfizer will also bring its first digital exhibit this year - the "3A Accelerate, Access, Associate" innovative solution for the full digitalization of patient journeys, showcasing its digital innovation achievements in various fields at the CIIE. It is reported that the program revolves around the concept of "patient-centered" and comprehensively covers all stages of the patient journey, including research and development, prevention, diagnosis, treatment, and disease management. It accelerates drug development and popularization through digital innovation, enhances patient accessibility to innovative drugs, and creates more valuable medical ecosystem connections.
As of now, Pfizer has transformed 10 innovative products that made their debut in China at the CIIE from exhibits to commodities. For example, the world's first and only CGRP (calcitonin gene-related peptide) receptor antagonist, orally disintegrating tablet remifentanil, which was unveiled at the CIIE last year, has been approved for market in China in January this year, bringing another breakthrough innovative solution to migraine patients in China. With the policy of "first in, first out" in Boao Lecheng, domestic patients with metastatic castration resistant prostate cancer have been treated with the innovative PARP inhibitor Terazopanib at Ruijin Hainan Hospital.